Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes von Holman, Rury R, Prof, Sourij, Harald, MD, Califf, Robert M, Prof

Volltext

Real-world studies no substitute for RCTs in establishing efficacy von Gerstein, Hertzel C, McMurray, John, Holman, Rury R

Volltext

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88 von Lind, Marcus, Imberg, Henrik, Coleman, Ruth L., Nerman, Olle, Holman, Rury R.

Volltext

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials von Zoungas, Sophia, Prof, Arima, Hisatomi, Prof, Gerstein, Hertzel C, Prof, Holman, Rury R, Prof, Woodward, Mark, Prof, Reaven, Peter, Prof, Hayward, Rodney A, Prof, Craven, Timothy, MSPH, Coleman, Ruth L, MSc, Chalmers, John, Prof

Volltext

Empagliflozin in acute myocardial infarction: the EMMY trial von von Lewinski, Dirk, Kolesnik, Ewald, Tripolt, Norbert J, Pferschy, Peter N, Benedikt, Martin, Wallner, Markus, Alber, Hannes, Berger, Rudolf, Lichtenauer, Michael, Saely, Christoph H, Moertl, Deddo, Auersperg, Pia, Reiter, Christian, Rieder, Thomas, Siller-Matula, Jolanta M, Gager, Gloria M, Hasun, Matthias, Weidinger, Franz, Pieber, Thomas R, Zechner, Peter M, Herrmann, Markus, Zirlik, Andreas, Holman, Rury R, Oulhaj, Abderrahim, Sourij, Harald

Volltext

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes von Holman, Rury R, Paul, Sanjoy K, Bethel, M. Angelyn, Matthews, David R, Neil, H. Andrew W

Volltext

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum von Cefalu, William T, Kaul, Sanjay, Gerstein, Hertzel C, Holman, Rury R, Zinman, Bernard, Skyler, Jay S, Green, Jennifer B, Buse, John B, Inzucchi, Silvio E, Leiter, Lawrence A, Raz, Itamar, Rosenstock, Julio, Riddle, Matthew C

Volltext

Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes von Holman, Rury R, Paul, Sanjoy K, Bethel, M. Angelyn, Neil, H. Andrew W, Matthews, David R

Volltext

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored von McMurray, John J V, Prof, Gerstein, Hertzel C, Prof, Holman, Rury R, Prof, Pfeffer, Marc A, Prof

Volltext

Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials von Zhou, Jin J., Coleman, Ruth, Holman, Rury R., Reaven, Peter

Volltext

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study von Shields, Beverley M., Dennis, John M., Angwin, Catherine D., Warren, Fiona, Henley, William E., Farmer, Andrew J., Sattar, Naveed, Holman, Rury R., Jones, Angus G., Pearson, Ewan R., Hattersley, Andrew T.

Volltext

β-cell secretory dysfunction: a key cause of type 2 diabetes von Holman, Rury R, Clark, Anne, Rorsman, Patrik

Volltext

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans von Baggio, Laurie L., Varin, Elodie M., Koehler, Jacqueline A., Cao, Xiemin, Lokhnygina, Yuliya, Stevens, Susanna R., Holman, Rury R., Drucker, Daniel J.

Volltext

Long‐term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85) von Maddaloni, Ernesto, Coleman, Ruth L., Pozzilli, Paolo, Holman, Rury R.

Volltext

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes von Holman, Rury R, Farmer, Andrew J, Davies, Melanie J, Levy, Jonathan C, Darbyshire, Julie L, Keenan, Joanne F, Paul, Sanjoy K

Volltext

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91) von Adler, Amanda I, Coleman, Ruth L, Leal, Jose, Whiteley, William N, Clarke, Philip, Holman, Rury R

Volltext

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Associati... von Nathan, David M, Buse, John B, Davidson, Mayer B, Ferrannini, Ele, Holman, Rury R, Sherwin, Robert, Zinman, Bernard

Volltext

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis von Kahn, Richard, Dr, Alperin, Peter, MD, Eddy, David, MD, Borch-Johnsen, Knut, MD, Buse, John, MD, Feigelman, Justin, Gregg, Edward, PhD, Holman, Rury R, MD, Kirkman, M Sue, MD, Stern, Michael, MD, Tuomilehto, Jaakko, MD, Wareham, Nick J, Prof

Volltext

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis von Bethel, M Angelyn, Patel, Rishi A, Merrill, Peter, Lokhnygina, Yuliya, Buse, John B, Mentz, Robert J, Pagidipati, Neha J, Chan, Juliana C, Gustavson, Stephanie M, Iqbal, Nayyar, Maggioni, Aldo P, Öhman, Peter, Poulter, Neil R, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F, Holman, Rury R

Volltext

Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes von Holman, Rury R, Thorne, Kerensa I, Farmer, Andrew J, Davies, Melanie J, Keenan, Joanne F, Paul, Sanjoy, Levy, Jonathan C

Volltext